Omnicell, Inc. (NASDAQ:OMCL) EVP Dan S. Johnston Sells 31,236 Shares of Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Dan S. Johnston sold 31,236 shares of the firm’s stock in a transaction that occurred on Tuesday, July 20th. The stock was sold at an average price of $151.35, for a total value of $4,727,568.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

OMCL opened at $151.28 on Thursday. The company has a quick ratio of 2.76, a current ratio of 3.09 and a debt-to-equity ratio of 0.47. The company has a 50 day simple moving average of $143.97. The firm has a market cap of $6.53 billion, a PE ratio of 79.66, a P/E/G ratio of 4.92 and a beta of 1.07. Omnicell, Inc. has a 12 month low of $65.21 and a 12 month high of $154.92.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, April 29th. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. The business had revenue of $251.84 million during the quarter, compared to analysts’ expectations of $245.35 million. Omnicell had a return on equity of 8.84% and a net margin of 3.83%. As a group, sell-side analysts expect that Omnicell, Inc. will post 2.55 EPS for the current fiscal year.

A number of research analysts recently issued reports on OMCL shares. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “sell” rating and set a $162.00 price target on the stock. in a research note on Friday, July 9th. Benchmark lifted their target price on Omnicell from $155.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, April 30th. Piper Sandler lifted their target price on Omnicell from $152.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, June 23rd. TheStreet downgraded Omnicell from a “b” rating to a “c+” rating in a research note on Friday, April 30th. Finally, BTIG Research started coverage on Omnicell in a research note on Monday, May 24th. They issued a “buy” rating and a $165.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $142.75.

Several institutional investors and hedge funds have recently bought and sold shares of OMCL. Neuberger Berman Group LLC acquired a new stake in shares of Omnicell in the 1st quarter valued at approximately $119,344,000. Norges Bank acquired a new stake in shares of Omnicell in the 4th quarter valued at approximately $62,233,000. Victory Capital Management Inc. lifted its holdings in shares of Omnicell by 1,362.3% in the 1st quarter. Victory Capital Management Inc. now owns 453,993 shares of the company’s stock valued at $58,960,000 after buying an additional 422,947 shares during the period. Oak Ridge Investments LLC raised its holdings in Omnicell by 735.7% during the first quarter. Oak Ridge Investments LLC now owns 419,589 shares of the company’s stock worth $54,492,000 after purchasing an additional 369,378 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in Omnicell by 4.5% during the first quarter. BlackRock Inc. now owns 6,965,056 shares of the company’s stock worth $904,552,000 after purchasing an additional 301,987 shares during the last quarter.

Omnicell Company Profile

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.

Read More: Do You Need a Fiduciary?

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.